Table 2 Baseline characteristics of patients with incident chronic obstructive pulmonary disease
Population 1 | Population 2 | |
|---|---|---|
20,704 | 10,988 | |
Male | 11,134 (53.8) | 5984 (54.5) |
Age (years) | ||
40–49 | 1070 (5.2) | 700 (6.4) |
50–59 | 3761 (18.2) | 2185 (19.9) |
60–69 | 6811 (32.9) | 3642 (33.1) |
70–79 | 6697 (32.3) | 3352 (30.5) |
≥ 80 | 2229 (10.8) | 1109 (10.1) |
COPD medication | ||
LAMA | 2429 (11.7) | 1251 (11.4) |
LABA | 749 (3.6) | 402 (3.7) |
LAMA/LABA | 1050 (5.1) | 494 (4.5) |
LABA/ICS | 4891 (23.6) | 2523 (23.0) |
LAMA/LABA/ICS | 604 (2.9) | 331 (3.0) |
Methylxanthines | 13,400 (64.7) | 7063 (64.3) |
Others | 10,217 (49.3) | 5336 (48.6) |
Comorbidity | ||
Asthma | 16,438 (79.4) | 8574 (78.0) |
Hyperlipidemia | 14,752 (71.3) | 7345 (66.8) |
Hypertension | 12,483 (60.3) | 6143 (55.9) |
Diabetes | 10,171 (49.1) | 4970 (45.2) |
Cerebrovascular disease | 4502 (21.7) | 2064 (18.8) |
Cancer | 3855 (18.6) | 1897 (17.3) |
Congestive heart failure | 3597 (17.4) | 1629 (14.8) |
Arrhythmia | 2515 (12.1) | 1164 (10.6) |
Bronchiectasis | 2089 (10.1) | 1069 (9.7) |
Renal disease | 870 (4.2) | 391 (3.6) |
Valvular disease | 353 (1.7) | 147 (1.3) |
Environmental lung disease | 182 (0.9) | 84 (0.8) |
Liver disease | 179 (0.9) | 94 (0.9) |
Quintiles for estimated household income | ||
1 | 1972 (9.5) | 834 (7.6) |
2 | 3457 (16.7) | 1862 (16.9) |
3 | 3369 (16.3) | 1832 (16.7) |
4 | 4724 (22.8) | 2590 (23.6) |
5 | 7182 (34.7) | 3870 (35.2) |